An observational study of glycemic control in canagliflozin treated patients

AbstractObjective:To evaluate changes in glycemic control following the initial canagliflozin pharmacy claim in a real-world population.Research design and methods:A retrospective cohort analysis of adult patients with type 2 diabetes mellitus (T2DM) was conducted using 2013 medical, pharmacy and laboratory claims from the Inovalon MORE2 Registry. Patients with T2DM aged ≥18 years with ≥60 days of canagliflozin supply and HbA1c test results within 120 days before and ≥60 days after initial canagliflozin claim (defined as index date) were included. The differences between HbA1c levels pre- and post-index were assessed. Changes pre- and post-index in Healthcare Effectiveness Data and Information Set (HEDIS) glycemic control criteria of HbA1c 9% were evaluated. Subgroup analyses of patients with HbA1c >7% at baseline and patients aged ≥65 were also conducted.Results:Among the 268 patients meeting the study criteria, mean HbA1c pre-index was 8.3% and post-index was 7.6%;...